001     141916
005     20240229105135.0
024 7 _ |a 10.1111/ejh.13100
|2 doi
024 7 _ |a pmid:29797671
|2 pmid
024 7 _ |a 0036-553X
|2 ISSN
024 7 _ |a 0902-4441
|2 ISSN
024 7 _ |a 1600-0609
|2 ISSN
024 7 _ |a altmetric:43234918
|2 altmetric
037 _ _ |a DKFZ-2018-02173
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Kriegsmann, Katharina
|0 0000-0002-3620-1491
|b 0
245 _ _ |a CD7 is expressed on a subset of normal CD34-positive myeloid precursors.
260 _ _ |a Oxford
|c 2018
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1544518621_4510
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a To improve monitoring of myeloid neoplasms by flow cytometry-based minimal residual disease (MRD) analysis, we analyzed the significance of leukemia-associated immunophenotype (LAIP) markers in 44 patients.In a pilot study cohort, peripheral blood or bone marrow samples from 13 patients with myeloid neoplasms and one case of B lymphoblastic leukemia in complete hematologic remission after allogeneic bone marrow or stem cell transplantation were subjected to selection for leukemia-specific phenotypes by fluorescence-activated cell sorting using individual marker combinations, followed by PCR-based chimerism analysis.The feasibility of this method could be demonstrated, with selection being successful in 12 cases, including two cases where mixed chimerism was found exclusively in sorted cells. Interestingly, four specimens displayed full donor chimerism in cells expressing the presumably aberrant combination CD34+ /CD7+ . Further analyses, including assessment of an independent cohort of 25 patients not affected by neoplastic bone marrow infiltration, revealed that normal myeloid precursors usually include a population coexpressing CD34, CD13, CD33, and CD7.We conclude that the combination CD34+ /CD7+ might not be suitable as an LAIP for MRD diagnostics and that a subset of normal myeloid precursors in the bone marrow expresses CD7.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Löffler, Harald
|0 P:(DE-He78)3d0bd280b309d8ef615f728f271a8595
|b 1
|u dkfz
700 1 _ |a Eckstein, Volker
|b 2
700 1 _ |a Schulz, Renate
|b 3
700 1 _ |a Kräker, Sandra
|b 4
700 1 _ |a Braun, Ute
|b 5
700 1 _ |a Luft, Thomas
|b 6
700 1 _ |a Hegenbart, Ute
|b 7
700 1 _ |a Schönland, Stefan
|b 8
700 1 _ |a Dreger, Peter
|b 9
700 1 _ |a Krämer, Alwin
|0 P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0
|b 10
|u dkfz
700 1 _ |a Ho, Anthony D
|b 11
700 1 _ |a Müller-Tidow, Carsten
|b 12
700 1 _ |a Hundemer, Michael
|b 13
773 _ _ |a 10.1111/ejh.13100
|g Vol. 101, no. 3, p. 318 - 325
|0 PERI:(DE-600)2027114-1
|n 3
|p 318 - 325
|t European journal of haematology
|v 101
|y 2018
|x 0902-4441
909 C O |o oai:inrepo02.dkfz.de:141916
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)3d0bd280b309d8ef615f728f271a8595
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|2 G:(DE-HGF)POF3-300
|v Translational cancer research
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J HAEMATOL : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)G330-20160331
|k G330
|l KKE Molekulare Hämatologie/Onkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G330-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21